We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 49.46 | 48.68 | 49.90 | 0 | 01:00:00 |
From May 2021 to May 2024
By Chris Wack
Sanofi Pasteur, the vaccines global business unit of Sanofi SA, and Translate Bio Inc. said they have begun a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.
The companies said the trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
Flu seasons that are dominated by A/H3N2 strain circulation activity tend to be more severe, especially among those considered at-risk such as older adults and younger children.
Sanofi and Translate Bio have developed and will evaluate two formulations of the vaccine in the Phase 1 influenza mRNA vaccine clinical trial. The two formulations differ in the lipid nanoparticle that contains the mRNA.
The trial follows successful preclinical research which demonstrated promising safety and immunogenicity.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 22, 2021 06:24 ET (10:24 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
